Detalhe da pesquisa
1.
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
Ann Oncol
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38729566
2.
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
Ann Oncol
; 33(6): 616-627, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35337972
3.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Ann Oncol
; 32(10): 1245-1255, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34224826
4.
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
Ann Oncol
; 32(2): 208-217, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33246021
5.
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Ann Oncol
; 31(8): 1001-1010, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32416251
6.
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Ann Oncol
; 31(3): 377-386, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32067679
7.
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Ann Oncol
; 30(3): 397-404, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30475950
8.
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.
Ann Oncol
; 30(8): 1381-1392, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31114846
9.
Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
Ann Oncol
; 29(5): 1195-1202, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29447329
10.
Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.
Ann Oncol
; 29(4): 881-887, 2018 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29481630
11.
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Ann Oncol
; 29(7): 1541-1547, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29718092
12.
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Ann Oncol
; 29(1): 154-161, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045554
13.
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.
Ann Oncol
; 28(3): 590-596, 2017 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27993804
14.
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
Ann Oncol
; 28(2): 313-320, 2017 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27803006
15.
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
Ann Oncol
; 28(1): 103-109, 2017 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28177480
16.
Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.
Breast Cancer Res Treat
; 162(3): 479-488, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28176175
17.
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Ann Oncol
; 27(7): 1249-56, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27052654
18.
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer.
Ann Oncol
; 27(1): 106-13, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26504153
19.
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
Ann Oncol
; 27(9): 1725-32, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27436849
20.
Changes in quality of life after a diagnosis of cancer: a 2-year study comparing breast cancer and melanoma patients.
Qual Life Res
; 25(8): 1969-79, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26886927